Abstract
The biopharmaceutical market has grown steadily since the early 1980s and today over 150 protein biopharmaceuticals have been approved for clinical use. These products often exhibit forms of immunotoxicity that often only come to light during clinical studies. The predictive value of animal studies and traditional in vitro screens is questionable, with few existing methods able to predict immunotoxicity in a way that is useful for estimating risk for entire patient populations for a specific, and often unique, product. Here, the relative merits of rational design and alternative strategies for immunotoxicity testing are considered with reference to the outcomes of preclinical and clinical studies on biopharmaceuticals. Specific reference is made to the prediction of immunogenicity using organotypic models, transgenic models of autoimmunity and immunogenicity as well as rodent models of hypersensitivity, immunosuppression and immunostimulation. The role played by human cell-based assays and in silico prediction models that have been developed and validated for the assessment of chemical classes is also appraised.
Keywords: Immunogenicity, immunosupression, immunostimulation, animal testing, organotypic, in vitro
Current Drug Safety
Title: Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Volume: 5 Issue: 4
Author(s): Nirmala Bhogal
Affiliation:
Keywords: Immunogenicity, immunosupression, immunostimulation, animal testing, organotypic, in vitro
Abstract: The biopharmaceutical market has grown steadily since the early 1980s and today over 150 protein biopharmaceuticals have been approved for clinical use. These products often exhibit forms of immunotoxicity that often only come to light during clinical studies. The predictive value of animal studies and traditional in vitro screens is questionable, with few existing methods able to predict immunotoxicity in a way that is useful for estimating risk for entire patient populations for a specific, and often unique, product. Here, the relative merits of rational design and alternative strategies for immunotoxicity testing are considered with reference to the outcomes of preclinical and clinical studies on biopharmaceuticals. Specific reference is made to the prediction of immunogenicity using organotypic models, transgenic models of autoimmunity and immunogenicity as well as rodent models of hypersensitivity, immunosuppression and immunostimulation. The role played by human cell-based assays and in silico prediction models that have been developed and validated for the assessment of chemical classes is also appraised.
Export Options
About this article
Cite this article as:
Bhogal Nirmala, Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment, Current Drug Safety 2010; 5 (4) . https://dx.doi.org/10.2174/157488610792246037
DOI https://dx.doi.org/10.2174/157488610792246037 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypersensitivity Reactions to Anticoagulant Drugs
Current Pharmaceutical Design Immunotherapy in Allergies: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity
Current Medicinal Chemistry Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Editorial [Hot Topic: An Update on the Diagnosis of Allergic and Non-Allergic Drug Hypersensitivity (Executive Editors: M.T. Ventura and A. Romano) ]
Current Pharmaceutical Design Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Treatment of Hereditary Angioedema: Current Perspectives
Recent Patents on Inflammation & Allergy Drug Discovery Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets Novel Drugs for Inflammatory Lung Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Serum Albumin Complexation of Acetylsalicylic Acid Metabolites
Current Drug Metabolism Allergy to Miscellaneous Household Arthropods
Protein & Peptide Letters Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids
Current Pharmaceutical Design